Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (RNAC)
Filing Type: Form 8-K (Current Report)
Report Date: April 30, 2026
Reporting Period: Quarter ended March 31, 2026
Business Context: The Company announced its financial results for the quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover sheet and does not contain specific numerical data. The following metrics are not disclosed in this document:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release containing the full announcement but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures, as they are not included in the 8-K cover sheet.
- Verify the specific revenue, net loss, and cash burn rate for the quarter ended March 31, 2026, in the full press release.
- Check for any updated clinical trial milestones or regulatory guidance mentioned in the press release.
- Confirm the Company's cash runway and liquidity position as of March 31, 2026.